Reuters logo
BRIEF-Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra
October 3, 2016 / 1:06 PM / a year ago

BRIEF-Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra

Oct 3 (Reuters) - VIVUS Inc :

* VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales

* VIVUS and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra

* VIVUS-Signed commercial supply agreement pursuant to which Co to be responsible for manufacture, supply of Stendra to Metuchen; VIVUS received $70 million Source text for Eikon: Further company coverage: ;))

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below